Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here’s what investors need to know before the announcement.
Analysts estimate that Inhibikase Therapeutics will report an earnings per share (EPS) of $-0.19.
Inhibikase Therapeutics bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Historical Earnings Performance
Last quarter the company missed EPS by $0.01, which was followed by a 1.63% increase in the share price the next day.
Here’s a look at Inhibikase Therapeutics’s past performance and the resulting price change:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.17 | -0.14 | -0.38 |
| EPS Actual | -0.18 | -0.20 | -0.18 | -0.22 |
| Price Change % | 1.63% | -2.7% | -6.31% | 6.15% |
Stock Performance
Shares of Inhibikase Therapeutics were trading at $0.8646 as of August 10. Over the last 52-week period, shares are down 51.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Inhibikase Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
